Cargando…

Hearing Benefits of Clinical Management for Meniere’s Disease

Meniere’s disease is a progressive hearing–disabling condition. Patients can benefit from strict clinical management, including lifestyle and dietary counseling, and medical treatment. A prospective cohort study was carried out with 154 patients with definite Meniere’s disease, with an average age o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Wei, Chenyi, Sun, Zhengtao, Wu, Yue, Chen, Zhengli, Liu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181791/
https://www.ncbi.nlm.nih.gov/pubmed/35683514
http://dx.doi.org/10.3390/jcm11113131
_version_ 1784723870919426048
author Zhang, Yi
Wei, Chenyi
Sun, Zhengtao
Wu, Yue
Chen, Zhengli
Liu, Bo
author_facet Zhang, Yi
Wei, Chenyi
Sun, Zhengtao
Wu, Yue
Chen, Zhengli
Liu, Bo
author_sort Zhang, Yi
collection PubMed
description Meniere’s disease is a progressive hearing–disabling condition. Patients can benefit from strict clinical management, including lifestyle and dietary counseling, and medical treatment. A prospective cohort study was carried out with 154 patients with definite Meniere’s disease, with an average age of 43.53 ± 11.40, and a male to female ratio of 0.97:1. The pure-tone thresholds of all 165 affected ears, over a one-year clinical management period, were analyzed. After one year, 87.27% of patients had improved or preserved their hearing at a low frequency, and 71.51% at a high frequency. The hearing threshold at frequencies from 250 Hz to 2000 Hz had improved significantly (p < 0.001, p < 0.001, p < 0.001, p < 0.01), and deteriorated slightly at 8000 Hz (p < 0.05). Of all the patients, 40.00% had a hearing average threshold that reached ≤25 dB HL after the clinical management period, among whom 27.27% were patients in stage 3. The restoration time was 2.5 (1.0, 4.125) months, with a range of 0.5–11.0 months, and the restoration time was longer for stage 3 than for stages 1 and 2 (u = −2.542, p < 0.05). The rising curves improved the most (p < 0.05), with most becoming peaks, whereas most peaks and flats remained the same. Patients who were initially in the earlier stages (95% CI 1.710~4.717, OR 2.840, p < 0.001), have an increased odds ratio of hearing by an average of ≤25 dB HL. Age (95% CI 1.003~1.074, OR 1.038, p = 0.031), peak curve (95% CI 1.038~5.945, OR = 2.484, p = 0.041), and flat curve (95% CI 1.056~19.590, OR = 4.549, p = 0.042), compared with the rising curve, increase the odds ratio of hearing on average by >25 dB HL. Most patients can have their hearing preserved or improved through strict clinical management, and sufficient follow-up is also essential. Stage 3 patients also have the potential for hearing improvement, although the restoration time is longer than in the early stages. The initial hearing stage, age, and audiogram pattern are related to the hearing benefits.
format Online
Article
Text
id pubmed-9181791
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91817912022-06-10 Hearing Benefits of Clinical Management for Meniere’s Disease Zhang, Yi Wei, Chenyi Sun, Zhengtao Wu, Yue Chen, Zhengli Liu, Bo J Clin Med Article Meniere’s disease is a progressive hearing–disabling condition. Patients can benefit from strict clinical management, including lifestyle and dietary counseling, and medical treatment. A prospective cohort study was carried out with 154 patients with definite Meniere’s disease, with an average age of 43.53 ± 11.40, and a male to female ratio of 0.97:1. The pure-tone thresholds of all 165 affected ears, over a one-year clinical management period, were analyzed. After one year, 87.27% of patients had improved or preserved their hearing at a low frequency, and 71.51% at a high frequency. The hearing threshold at frequencies from 250 Hz to 2000 Hz had improved significantly (p < 0.001, p < 0.001, p < 0.001, p < 0.01), and deteriorated slightly at 8000 Hz (p < 0.05). Of all the patients, 40.00% had a hearing average threshold that reached ≤25 dB HL after the clinical management period, among whom 27.27% were patients in stage 3. The restoration time was 2.5 (1.0, 4.125) months, with a range of 0.5–11.0 months, and the restoration time was longer for stage 3 than for stages 1 and 2 (u = −2.542, p < 0.05). The rising curves improved the most (p < 0.05), with most becoming peaks, whereas most peaks and flats remained the same. Patients who were initially in the earlier stages (95% CI 1.710~4.717, OR 2.840, p < 0.001), have an increased odds ratio of hearing by an average of ≤25 dB HL. Age (95% CI 1.003~1.074, OR 1.038, p = 0.031), peak curve (95% CI 1.038~5.945, OR = 2.484, p = 0.041), and flat curve (95% CI 1.056~19.590, OR = 4.549, p = 0.042), compared with the rising curve, increase the odds ratio of hearing on average by >25 dB HL. Most patients can have their hearing preserved or improved through strict clinical management, and sufficient follow-up is also essential. Stage 3 patients also have the potential for hearing improvement, although the restoration time is longer than in the early stages. The initial hearing stage, age, and audiogram pattern are related to the hearing benefits. MDPI 2022-05-31 /pmc/articles/PMC9181791/ /pubmed/35683514 http://dx.doi.org/10.3390/jcm11113131 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Yi
Wei, Chenyi
Sun, Zhengtao
Wu, Yue
Chen, Zhengli
Liu, Bo
Hearing Benefits of Clinical Management for Meniere’s Disease
title Hearing Benefits of Clinical Management for Meniere’s Disease
title_full Hearing Benefits of Clinical Management for Meniere’s Disease
title_fullStr Hearing Benefits of Clinical Management for Meniere’s Disease
title_full_unstemmed Hearing Benefits of Clinical Management for Meniere’s Disease
title_short Hearing Benefits of Clinical Management for Meniere’s Disease
title_sort hearing benefits of clinical management for meniere’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181791/
https://www.ncbi.nlm.nih.gov/pubmed/35683514
http://dx.doi.org/10.3390/jcm11113131
work_keys_str_mv AT zhangyi hearingbenefitsofclinicalmanagementformenieresdisease
AT weichenyi hearingbenefitsofclinicalmanagementformenieresdisease
AT sunzhengtao hearingbenefitsofclinicalmanagementformenieresdisease
AT wuyue hearingbenefitsofclinicalmanagementformenieresdisease
AT chenzhengli hearingbenefitsofclinicalmanagementformenieresdisease
AT liubo hearingbenefitsofclinicalmanagementformenieresdisease